JAK inhibitors and COVID-19
JAK 억제제 및 COVID-19
Review
[키워드] activated
added
Antiviral
antiviral molecules
Autoimmunity
Baricitinib
benefit
clinical experience
clinical trials
coded
concerning
contributing to
COVID-19
COVID-19 treatment
cut-off
cytokine
Cytokine storm
Cytokines
differentiation
Effect
Effects
Evolution
family
Graft
hematologic
hematologic neoplasms
Human genome
immune regulation
immune response
Immunosuppression
immunosuppressive effect
immunosuppressive effects
indicated
induce
inhibited
innate immune response
interferons
involved
issue
Jak
JAK inhibitor
jak inhibitors
JAK1
JAK2
JAK3
JAKi
janus
Janus kinase
kinases
Meta-analysis
moment
Neoplasms
nezulcitinib
outcome
pathogenic
pathway
Pathways
patients treated
patients with COVID-19
Phase 3 trials
proliferation
randomized clinical trial
RCT
reaction
receptor
reduce mortality
rheumatic disease
Rheumatic diseases
risk reduction
ruxolitinib
SARS-COV-2 infection
severe COVID-19
Side effect
Signaling
Significant
Standard of care
subsequent
suggested
survival
the SARS-CoV-2
the WHO
Therapies
therapies, investigational.
Tofacitinib
transmembrane
Treatment
trials
TYK2
Type I IFN
type I interferons
Viral
viral replication
virus clearance
[DOI] 10.1136/jitc-2021-002838 PMC 바로가기 [Article Type] Review
[DOI] 10.1136/jitc-2021-002838 PMC 바로가기 [Article Type] Review